Bicycle Therapeutics vs Protalix Biotherapeutics
Bicycle Therapeutics is the larger business, with $72.6m of revenue in fiscal 2025 against $52.7m for Protalix Biotherapeutics (1.4 times as much). Bicycle Therapeutics grew faster (105.8% against -1.2%). Protalix Biotherapeutics kept more of each dollar of sales as profit: a net margin of -12.5% against -301.7%. Bicycle Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Bicycle TherapeuticsBCYC, 2025 | Protalix BiotherapeuticsPLX, 2025 |
|---|---|---|
| Revenue | $72.6m | $52.7m |
| Revenue growth | 105.8% | -1.2% |
| Net income | −$219m | −$6.6m |
| Operating margin | -340.4% | -10.4% |
| Net margin | -301.7% | -12.5% |
| Return on equity | -31.2% | -14.4% |
| Free cash flow | −$252m | −$13.6m |
| Cash | $628m | $14.7m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 288 | 226 |
| Market value | $253m | $206m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 1 sales |